Clinical trials: Genital Neoplasms
Advanced Cancer
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with…
- Trial name
- NCT03674567
- Testing
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Infection, Precancerous Condition
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine…
- Trial name
- NCT00513526
- Testing
- Gardasil
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- AIDS Malignancy Consortium
BRCA1 Mutation, BRCA2 Mutation
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Ovarian cancer is the most fatal gynecologic cancer; in the US alone an estimated 22,000 women will be diagnosed in 2019, with over 13,000 dying of the disease.
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT04598321
- Testing
- Talazoparib Oral Capsule
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Ovarian Neoplasms
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
This is a Phase II, randomized, multi-centre study aiming at comparing the efficacy of Olaparib and Cediranib vs. weekly Paclitaxel in terms of progression free survival (PFS) in platinum refractory or resistant recurrent ovarian…
- Trial name
- BAROCCO (NCT03314740)
- Testing
- Paclitaxel, Cediranib, Olaparib
- Where
- 6 sites in Italy
- Volunteers
- 123 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Prostate Cancer
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose…
- Trial name
- NCT03120832
- Testing
- PAN-301-1
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Polycystic Ovary Syndrome
Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)
Our hypothesis is that hyperinsulinemia increases the renal clearance of D-chiro-inositol (DCI) in women with polycystic ovary syndrome (PCOS) and that this leads to a reduction in circulating insulin-stimulated…
- Trial name
- PCOS (NCT00868140)
- Testing
- pioglitazone
- Where
- 2 sites in United States, Venezuela
- Volunteers
- 51 people
- Sponsor
- Virginia Commonwealth University
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
VMAT for Dominant Intraprostatic Lesion
The aim of this study was to determine the efficacy and safety of the implementation of a program of " image-guided focal Intensification dose to intraprostatic dominant lesion " in men with localized prostate cancer (PCa) of…
- Trial name
- CaP-VMAT-DIL (NCT03030625)
- Testing
- IGRT/VMAT focal therapy boost to DIL
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Lymphoma, Nonneoplastic Condition
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00822120
- Testing
- bleomycin sulfate, filgrastim, ABVD regimen
- Where
- 423 sites in United States
- Volunteers
- 371 people
- Sponsor
- SWOG Cancer Research Network
Cervical Intraepithelial Neoplasia
Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion
The purpose of this trial is to determine whether SWETZ (Straight Wire Excision of Transformation Zone) is a superior alternative to LLETZ cone (Large Loop Excision of Transformation Zone cone biopsy) in the management of…
- Trial name
- NCT00995020
- Testing
- Straight Wire Excision of Transformation Zone, Large Loop Excision of Transformation Zone (cone biopsy)
- Where
- 2 sites in Brazil
- Volunteers
- 103 people
- Sponsor
- Oswaldo Cruz Foundation
Prostate Cancer
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
- Trial name
- CheckMate 9KD (NCT03338790)
- Testing
- nivolumab, docetaxel, enzalutamide
- Where
- 66 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
A Trial of Degarelix in Patients With Prostate Cancer
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
- Trial name
- NCT00946920
- Testing
- Degarelix, Goserelin acetate
- Where
- 126 sites in United States, Belgium and 12 more
- Volunteers
- 859 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer, Prostatic Neoplasms
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy for recurrent prostate cancer.
- Trial name
- NCT00878436
- Testing
- Panobinostat, Bicalutamide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- NYU Langone Health
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to look at how patients respond to treatment with guadecitabine and pembrolizumab. The researchers will also be looking at the amount of time it takes for cancer to get worse when participants take…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02901899
- Testing
- Guadecitabine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- NCT04887506
- Testing
- TAVT-45, Zytiga, Prednisone
- Where
- 42 sites in United States, France and 6 more
- Volunteers
- 107 people
- Sponsor
- Tavanta Therapeutics
Prostatic Neoplasms, Genital Neoplasms, Male
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Trial name
- NCT04461509
- Testing
- 18F-PSMA
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Alessandro D'Agnolo
Prostatic Neoplasms, Prostatic Cancer
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Background: Metastatic castration resistant prostate cancer (mCRPC) keeps growing even when the amount of testosterone in the body is reduced to very low levels. mCRPC is incurable.
- Trial name
- NCT03481816
- Testing
- ETBX-071; adenoviral PSA vaccine, ETBX-061; adenoviral MUC1 vaccine, ETBX-051; adenoviral brachyury vaccine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Cervical Cancer
Clinic-based Intervention to Promote Cervical Cancer Prevention Behaviors
The project is a clinical behavioral research project based at University of Pennsylvania. The goal of this research is to design a brief clinic-based, Nurse Practitioner-guided, and theory-based health promotion intervention to…
- Trial name
- StepUp (NCT02046265)
- Testing
- Step Up to Prevention, Step Up to Prevention: knowledge, Step Up to Prevention:belief
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
Cervical cancer is the second most common cancer among women worldwide. Approximately 500 000 new cases are reported each year worldwide, from which 83% occur in developing countries.
- Trial name
- NCT00481767
- Testing
- Cervarix
- Where
- 2 sites in Senegal, Tanzania
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.